Recurrent activating mutations of CD28 in peripheral T-cell lymphomas

Leukemia

Volumn 30, Issue 5, 2016, Pages 1062-1070

  Rohr, J ^a,b   Guo, S ^c   Huo, J ^d   Bouska, A ^a   Lachel, C ^a   Li, Y ^b   Simone, P D ^e   Zhang, W ^a   Gong, Q ^b   Wang, C ^a,b,f   Cannon, A ^a   Heavican, T ^a   Mottok, A ^g,h   Hung, S ^g,h   Rosenwald, A ⁱ   Gascoyne, R ^g,h   Fu, K ^a   Greiner, T C ^a   Weisenburger, D D ^b   Vose, J M ^a   Staudt, L M ^j   Xiao, W ^k   Borgstahl, G E O ^l   Davis, S ^d   Steidl, C ^g,h   McKeithan, T ^b   Iqbal, J ^a   Chan, W C ^b   more..

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e FLORIDA ATLANTIC UNIVERSITY   (United States)

^f SHANDONG UNIVERSITY   (China)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD226 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; GRAP2 PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTEIN BINDING; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; JURKAT CELL LINE; MAJOR CLINICAL STUDY; MOLECULAR MODEL; MUTANT; MUTATIONAL ANALYSIS; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; SURFACE PLASMON RESONANCE;

ANTIGENS, CD28; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MODELS, MOLECULAR; MUTATION; NF-KAPPA B; PROTEIN BINDING; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955306513     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.357     Document Type: Article

References (60)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111: 4463-4470.
3. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 4952-4963.
4. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026-1036.
5. Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioim-munoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood 2006; 108: 1110-1111.
6. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
7. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119: 1901-1903.
8. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 2015; 126: 1741-1752.
9. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123: 1293-1296.
10. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166-170.
11. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171-175.
12. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 371-375.
13. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915-2923.
14. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood 2013; 121: 734-744.
15. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586-6590.
16. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003; 3: 544-556.
17. Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol 2010; 2: a002436.
18. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
19. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
20. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-515.
21. Yost SE, Alakus H, Matsui H, Schwab RB, Jepsen K, Frazer KA et al. Mutascope: sensitive detection of somatic mutations from deep amplicon sequencing. Bioinformatics 2013; 29: 1908-1909.
22. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
23. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 2011; 12: R72.
24. Therneau T (2015). A Package for Survival Analysis in S. version 2.38. Available from http://CRAN.R-project.org/package=survival.
25. Evans EJ, Castro MA, O'Brien R, Kearney A, Walsh H, Sparks LM et al. Crystal structure and binding properties of the CD2 and CD244 (2B4)-binding protein, CD48. J Biol Chem 2006; 281: 29309-29320.
26. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-210.
27. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185: 393-403.
28. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol 2005; 6: 271-279.
29. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 2001; 410: 604-608.
30. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001; 410: 608-611.
31. Higo K, Ikura T, Oda M, Morii H, Takahashi J, Abe R et al. High resolution crystal structure of the Grb2 SH2 domain with a phosphopeptide derived from CD28. PLoS One 2013; 8: e74482.
32. Simone PD, Struble LR, Kellezi A, Brown CA, Grabow CE, Khutsishvili I et al. The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core. J Struct Biol 2013; 182: 197-208.
33. Simone LC, Georgesen CJ, Simone PD, Wang X, Solheim JC. Productive association between MHC class I and tapasin requires the tapasin transmembrane/cytosolic region and the tapasin C-terminal Ig-like domain. Mol Immunol 2013; 49: 628-639.
34. Krishna SS, Aravind L, Bakolitsa C, Caruthers J, Carlton D, Miller MD et al. The structure of SSO2064, the first representative of Pfam family PF01796, reveals a novel two-domain zinc-ribbon OB-fold architecture with a potential acyl-CoA-binding role. Acta Crystallogr Sect F Struct Biol Cryst Commun 2010; 66: 1160-1166.
35. Kucuk C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA 2011; 108: 20119-20124.
36. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317-325.
37. Weinstein JS, Lezon-Geyda K, Maksimova Y, Craft S, Zhang Y, Su M et al. Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes. Blood 2014; 124: 3719-3729.
38. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015; 47: 1011-1019.
39. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604-8610.
40. Sekulic A, Liang WS, Tembe W, Izatt T, Kruglyak S, Kiefer JA et al. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med 2015; 3: 130-136.
41. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga JI et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 2015; 47: 1304-1315.
42. Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 2015; 6: 6025.
43. Bajorath J, Metzler WJ, Linsley PS. Molecular modeling of CD28 and three-dimensional analysis of residue conservation in the CD28/CD152 family. J Mol Graph Model 1997; 15: 135-139, 08-11.
44. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and inter-leukin 2 mRNA accumulation. J Exp Med 1991; 173: 721-730.
45. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
46. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
47. Watanabe R, Harada Y, Takeda K, Takahashi J, Ohnuki K, Ogawa S et al. Grb2 and Gads exhibit different interactions with CD28 and play distinct roles in CD28-mediated costimulation. J Immunol 2006; 177: 1085-1091.
48. Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 2003; 31: 3635-3641.
49. Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 2003; 125: 1731-1737.
50. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA 2002; 99: 11790-11795.
51. Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109: 5002-5010.
52. Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 1998; 4: 1521-1526.
53. Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 2000; 96: 1274-1279.
54. Lee SH, Kim JS, Kim J, Kim SJ, Kim WS, Lee S et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica 2015; 100: e505-e507.
55. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD et al. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 2010; 464: 932-936.
56. Cefai D, Schneider H, Matangkasombut O, Kang H, Brody J, Rudd CE. CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. J Immunol 1998; 160: 2223-2230.
57. Seth S, Ravens I, Kremmer E, Maier MK, Hadis U, Hardtke S et al. Abundance of follicular helper T cells in Peyer's patches is modulated by CD155. Eur J Immunol 2009; 39: 3160-3170.
58. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-937.
59. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003; 278: 36916-36923.
60. Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X. DOG 1.0: illustrator of protein domain structures. Cell Res 2009; 19: 271-273.